NOVEL TRIAZOLE DERIVATIVES WITH IMPROVED RECEPTOR ACTIVITY AND BIOAVAILABILITY PROPERTIES AS GHRELIN ANTAGONISTS OF GROWTH HORMONE SECRETAGOGUE RECEPTORS
The present invention provides novel triazole derivatives with improved receptor activity and bioavailability properties as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and/or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors. The present invention further provides GHS receptor antagonists and agonists that can be used for modulation of these receptors and are useful for treating above conditions, in particular alcohol disorder drug abuse growth retardation cachexia short-, medium- and/or long term regulation of energy balance short-, medium- and/or long term regulation (stimulation and/or inhibition) of food intake intake of rewarding food adipogenesis adiposity and/or obesity body weight gain and/or reduction diabetes, diabetes type I, diabetes type II tumor cell proliferation inflammation inflammatory effects gastric postoperative ileus postoperative ileus and/or gastrectomy (ghrelin replacement therapy)".
